Takeda to Pay $6 Billion in Actos Cancer Lawsuits
On April 7, 2014, a federal court in Louisiana ordered Japanese drug maker Takeda Pharmaceutical Co. Ltd. to pay $6 billion in punitive damages in settlement of allegations that the company concealed information regarding the risk for cancer associated with its diabetes drug Actos. Eli Lilly and Co., a co-defendant in the case, was ordered to pay $3 billion in punitive damages and $1.45 billion in compensatory damages. This was the first federal case to be tried in a consolidated multidistrict litigation comprising of more than 2,900 lawsuits.
Actos is a member of class of drugs known as thiazolidinediones, used to treat type 2 diabetes. The side effects of Actos include increased risk for bladder cancer, congestive heart failure, serious liver problems, and fractures. According to Eli Lilly and Co., 75 percent of the liability was allocated to Takeda and 25 percent to Lilly. Takeda plans to appeal the award, stating that judgments were entered in its favor in all three previous Actos trials.
If you or someone you know has been affected by the drug Actos, please contact Khorrami Boucher, LLP for a consultation.